New lipid therapies: PCSK9 inhibitors

New lipid therapies: PCSK9 inhibitors

Pharmacologic therapy reduces cardiovascular risk in a variety of primary and secondary prevention clinical situations in addition to lifestyle modifications. Low density lipoprotein cholesterol (LDL-C) is a key mediator of atherogenesis. Most cholesterol guidelines propose specific LDL-C while rece...

Full description

Bibliographic Details
Main Authors:	Farah Meah, DO, Arshi Basit, MD, Alaleh Mazhari, DO, Mary Ann Emanuele, MD, Nicholas Emanuele, MD
Format:	Article
Language:	English
Published:	Elsevier 2016-12-01
Series:	Journal of Clinical and Translational Endocrinology Case Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214624516300132

Similar Items

PCSK 9 inhibitors: A short history and a new era of lipid-lowering therapy
by: Rachel Hajar
Published: (2019-01-01)

PCSK9: A New Target for Lipid-Lowering Therapy
by: Nutjaree Jeenduang
Published: (2014-04-01)

PCSK9 inhibitors as a therapy for hypercholesterolemia
by: Nofal, Maia
Published: (2016)

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
by: Bruce A. Warden, PharmD, et al.
Published: (2020-03-01)

LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy
by: Hamasaki, M., et al.
Published: (2021)

Naturally Occurring PCSK9 Inhibitors
by: Maria Pia Adorni, et al.
Published: (2020-05-01)

Pleiotropic Effects of PCSK-9 Inhibitors
by: Marcin Basiak, et al.
Published: (2021-03-01)

PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions
by: Lοukianos S. Rallidis, et al.
Published: (2016-03-01)

Circulating PCSK9 and Risk of Myocardial Infarction
by: Lars E. Laugsand, MD, PhD, et al.
Published: (2016-12-01)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01)

Cholesterol and stroke: role of PCSK9 inhibitors
by: L. Castilla-Guerra, et al.
Published: (2019-04-01)

PCSK9 inhibitors in clinical practice: Novel directions and new experiences
by: Loukianos S. Rallidis, et al.
Published: (2020-07-01)

Finding inhibitors for PCSK9 using computational methods
by: Rida Zainab, et al.
Published: (2021-01-01)

Finding inhibitors for PCSK9 using computational methods.
by: Rida Zainab, et al.
Published: (2021-01-01)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
by: Kosmas CE, et al.
Published: (2020-12-01)

Practical guide for the use of PCSK9 inhibitors in Portugal
by: Ricardo Fontes-Carvalho, et al.
Published: (2019-06-01)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
by: Brian Tomlinson, et al.
Published: (2021-04-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
by: Ye-Xuan Cao, et al.
Published: (2019-11-01)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
by: Gaojun Cai, et al.
Published: (2018-09-01)

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01)

PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease
by: Natalia Pauli, et al.
Published: (2020-07-01)

PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
by: EBioMedicine
Published: (2015-12-01)

PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.
by: Yascara Grisel Luna Saavedra, et al.
Published: (2013-01-01)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
by: Constantine E Kosmas, et al.
Published: (2017-11-01)

The PCSK9 decade
by: Gilles Lambert, et al.
Published: (2012-12-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
by: Ioanna Andreadou, et al.
Published: (2020-11-01)

PCSK9 Inhibitors in the Treatment of Cardiovascular Diseases: A Narrative Review
by: Francisco Freire Barbas de Albuquerque
Published: (2019)

Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation.
by: Michael Kühl, et al.
Published: (2019-01-01)

An investigation into statins, PCSK9 inhibitors, and other current cholesterol treatments
by: Kiley, Mark E.
Published: (2018)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy
by: Lillian Smith, et al.
Published: (2016-03-01)

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
by: Cinquegrani, M., et al.
Published: (2022)

Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease
by: Borja Quiroga, et al.
Published: (2020-09-01)

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
by: Tingting Li, et al.
Published: (2021-01-01)

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
by: Paul C Langley, Dr
Published: (2017-05-01)

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
by: Paulo Eduardo Ballvé Behr, et al.

Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors
by: Hines DM, et al.
Published: (2018-12-01)

Cannot write session to /tmp/vufind_sessions/sess_7tha1un1j13nsv28hafu46drdp